TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatme...
Leadership
Philippe P. Calais Ph.D., Pharm., Pharm.D.
CEO & Executive Chairman of the Board
Thomas A. Fitzgerald M.B.A.
CFO, President, VP of Administration & Director
Zdravka Medarova Ph.D.Founder
Scientific Co-Founder & Chief Scientific Officer
Anna Moore Ph.D.Founder
Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board